European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

PANcreatic CAncer Initial Detection via liquid biopsy

Description du projet

DE EN ES FR IT PL

Un test sanguin pour le diagnostic du cancer du pancréas

Les tumeurs libèrent de minuscules quantités de cellules ou de matériel cellulaire dans la circulation sanguine. Si ce phénomène constitue la base du potentiel de diagnostic des biopsies liquides, celles-ci pâtissent souvent d’une sensibilité ou d’une spécificité réduite. Le projet PANCAID, financé par l’UE, s’attache à mettre au point un test de diagnostic du cancer du pancréas, l’une des principales causes de décès attribuables au cancer dans le monde. Ce test combinera une série de biomarqueurs et l’IA à des fins d’analyse, ce qui permettra d’obtenir une précision et une sensibilité élevées. Le pronostic du cancer du pancréas étant extrêmement défavorable, le test PANCAID devrait contribuer à la détection précoce pour une meilleure prise en charge et de meilleurs résultats cliniques.

Objectif

Pancreatic cancer (PDAC) is usually detected at late stages and most patients die within one year after diagnosis. In PANCAID we will therefore develop a blood test for early detection of PDAC. Despite tremendous technological advances in Liquid Biopsy Diagnostics (LBx), this goal is very ambitious because small tumors release only minute amounts of cells or cellular products (e.g. DNA, RNA, protein, metabolites) into the circulation. Thus, tests with a high sensitivity are required but increases in sensitivity are usually achieved on the expenses of reduced specificity which can lead to significant overdiagnosis leading to unnecessary stress for the individuals with a false-positive blood test and high costs for the health system. In PANCAID, we will therefore establish a blood test with high accuracy by analyzing large cohorts of patients with PDAC and its precursor lesions, individuals at risk to develop PDAC and appropriate age-matched control groups (healthy and non-cancer diseases frequent in the targeted population).
Ambitious objectives of PANCAID include (1) establishment of a unique resource of blood samples of early PDAC and risk groups (WP1); (2) Establishment of a breakthrough blood test for early diagnosis of PDAC (WP2); (3) Identification of the best composite biomarker panel by integrating multimodal features in an AI-assisted computational analysis; (4) Analysis of the socio-economic impact of early PDAC diagnosis (WP4); and (5) Definition of the ethics parameters relevant to early PDAC detection (WP5). A robust multi-biomarker panel will be determined during the training period (year 1-3) and subsequently validated on bio-banked blood samples (year 4-5). Depending on the outcome of this comprehensive analysis, PANCAID will provide the design of a future prospective study for validation of the developed composite blood test in an international multi-center setting required to introduce LBx into screening programs for high-risk individuals. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening’.

Champ scientifique

Mots‑clés

Programme(s)

Thème(s)

Appel à propositions

HORIZON-MISS-2021-CANCER-02

Voir d’autres projets de cet appel

Régime de financement

HORIZON-RIA - HORIZON Research and Innovation Actions

Coordinateur

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Contribution nette de l'UE
€ 2 114 223,75
Adresse
Martinistrasse 52
20251 Hamburg
Allemagne

Voir sur la carte
Région
Hamburg Hamburg Hamburg
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 2 114 223,75

Participants (18)

Partenaires (1)

Partager cette page

Télécharger

Dernière mise à jour: 30 Decembre 2022

Mon livret

Permalink: https://cordis.europa.eu/project/id/101096309/fr

European Union, 2024